A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Hypersomnia
- Focus Registrational; Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 29 Nov 2018 According to a Jazz Pharmaceuticals plc media release, first patient has been enrolled in the trial.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Jazz Pharmaceuticals plc media release.
- 18 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.